Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
- PMID: 39602624
- DOI: 10.1056/NEJMoa2411858
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
Abstract
Background: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender women, transgender men, and gender-nonbinary persons is unclear.
Methods: In this phase 3, double-blind, randomized, active-controlled trial, we randomly assigned participants in a 2:1 ratio to receive subcutaneous lenacapavir every 26 weeks or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF). The primary efficacy analysis compared the incidence of HIV infection in the lenacapavir group with the background HIV incidence in the screened population. The secondary efficacy analysis compared the incidence of HIV infection in the lenacapavir group with that in the F/TDF group.
Results: Among 3265 participants who were included in the modified intention-to-treat analysis, HIV infections occurred in 2 participants in the lenacapavir group (0.10 per 100 person-years; 95% confidence interval [CI], 0.01 to 0.37) and in 9 participants in the F/TDF group (0.93 per 100 person-years; 95% CI, 0.43 to 1.77). The background HIV incidence in the screened population (4634 participants) was 2.37 per 100 person-years (95% CI, 1.65 to 3.42). The incidence of HIV infection in the lenacapavir group was significantly lower than both the background incidence (incidence rate ratio, 0.04; 95% CI, 0.01 to 0.18; P<0.001) and the incidence in the F/TDF group (incidence rate ratio, 0.11; 95% CI, 0.02 to 0.51; P = 0.002). No safety concerns were identified. A total of 26 of 2183 participants (1.2%) in the lenacapavir group and 3 of 1088 (0.3%) in the F/TDF group discontinued the trial regimen because of injection-site reactions.
Conclusions: The HIV incidence with twice-yearly lenacapavir was significantly lower than the background incidence and the incidence with F/TDF. (Funded by Gilead Sciences; PURPOSE 2 ClinicalTrials.gov number, NCT04925752.).
Copyright © 2024 Massachusetts Medical Society.
Comment in
-
Better PrEParation for HIV prevention in minority groups.Nat Rev Urol. 2025 Jan;22(1):4. doi: 10.1038/s41585-024-00981-w. Nat Rev Urol. 2025. PMID: 39643670 No abstract available.
Similar articles
-
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.N Engl J Med. 2024 Oct 3;391(13):1179-1192. doi: 10.1056/NEJMoa2407001. Epub 2024 Jul 24. N Engl J Med. 2024. PMID: 39046157 Clinical Trial.
-
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.Lancet HIV. 2023 Dec;10(12):e767-e778. doi: 10.1016/S2352-3018(23)00261-8. Epub 2023 Nov 9. Lancet HIV. 2023. PMID: 37952550 Free PMC article. Clinical Trial.
-
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.Lancet. 2022 May 7;399(10337):1779-1789. doi: 10.1016/S0140-6736(22)00538-4. Epub 2022 Apr 1. Lancet. 2022. PMID: 35378077 Free PMC article. Clinical Trial.
-
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.Cochrane Database Syst Rev. 2016 May 9;2016(5):CD000544. doi: 10.1002/14651858.CD000544.pub4. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 Aug 28;8:CD000544. doi: 10.1002/14651858.CD000544.pub5. PMID: 27158764 Free PMC article. Updated. Review.
-
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi: 10.1002/14651858.CD000543.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2016 Apr 21;4:CD000543. doi: 10.1002/14651858.CD000543.pub4. PMID: 23076889 Updated. Review.
Associated data
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous